Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.34 |
| ▸ | CALML3 | P27482 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Posizolid SCHEMBL7079325 | 1.00 | MAOA (0.34) | MAOACALML3CYP2C9CYP2C19GRM2 | |
| Posizolid SCHEMBL14286008 | 1.00 | MAOA (0.34) | MAOACALML3CYP2C9CYP2C19GRM2 | |
| Posizolid SCHEMBL3039615 | 1.00 | MAOA (0.34) | MAOACALML3CYP2C9CYP2C19GRM2 | |
| SCHEMBL7081128 | 0.94 | MAOA (0.34) | MAOACALML3GRM2MAOBF10 | |
| SCHEMBL7081127 | 0.94 | MAOA (0.34) | MAOACALML3GRM2MAOBF10 | |
| SCHEMBL19486038 | 0.93 | MAOA (0.34) | MAOACALML3CYP2C9CYP2C19MAOB | |
| SCHEMBL7079423 | 0.93 | CALML3 (0.34) | MAOACALML3CYP2C9CYP2C19GRM2 | |
| SCHEMBL7077028 | 0.92 | MAOA (0.32) | MAOACALML3CYP2C9CYP2C19GRM2 | |
| SCHEMBL12673656 | 0.92 | GRM2 (0.34) | MAOAGRM2MAOBF10 | |
| SCHEMBL7077025 | 0.92 | MAOA (0.32) | MAOACALML3GRM2MAOBF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2668 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727950-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2026-04-22 | — | — | EP | claimed |
| US-20260048047-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | SCRIPPS RESEARCH INST (US) | 2026-02-19 | — | — | US | claimed |
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | ATOPIC MEDICAL INC (US) | 2026-01-29 | — | — | US | claimed |
| US-12465623-B2 | Use of parasites and extracellular vesicles obtained from parasites in cancer treatment | YEDITEPE UNIVERSITESI (TR) | 2025-11-11 | — | — | US | claimed |
| EP-3965808-B1 | USE OF PARASITES AND EXTRACELLULAR VESICLES OBTAINED FROM PARASITES IN CANCER TREATMENT | UNIV YEDITEPE (TR) | 2025-09-03 | — | — | EP | claimed |
| WO-2025096495-A1 | ARYL FLUOROSULFATE-BASED INHIBITORS AS NOVEL ANTITUBERCULAR AGENTS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-05-08 | — | — | WO | claimed |
| US-12285489-B2 | Bone targeted antimicrobial oxazolidinone related compounds, formulations thereof, and uses thereof | EBETINO FRANK HALLOCK (US) | 2025-04-29 | — | — | US | claimed |
| US-20250129084-A1 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-04-24 | — | — | US | claimed |
| WO-2025080590-A1 | CO-CRYSTALLIZATION OF ACTIVES WITH SACCHARIDE-BASED MOLECULAR FRAMEWORKS | SCIENTIFIC HORIZONS CONSULTING LLC (US) | 2025-04-17 | — | — | WO | claimed |
| EP-4486454-A1 | COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-01-08 | — | — | EP | claimed |
| WO-2011037731-A1 | BORON CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-03-31 | — | — | WO | claimed |
| WO-2010106355-A1 | COMPOUND FOR THE TREATMENT OF TUBERCULOSIS | ASTRAZENECA AB (SE) | 2010-09-23 | — | — | WO | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-6617339-B1 | 5-Isoxazolyloxymethyl-3-((dihydroxypropanoyl)-4-tetrahydropyri dyl-3,5- difluorophenyl)oxazolidinone, or the phosphated derivative or its disodium salt; antibiotic with useful activity against Grampositive pathogens | SYNGENTA LIMITED (GB) | 2003-09-09 | — | — | US | claimed |
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | SYNGENTA LIMITED (GB) | 2003-07-31 | — | — | US | claimed |
| EP-1082323-A2 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AstraZeneca UK Limited (GB) | 2001-03-14 | — | — | EP | claimed |
| WO-1999064417-A2 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 1999-12-16 | — | — | WO | claimed |